Masafumi Kawanishi

Phase II/III Results of a Trial of Anti–Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis

Tsutomu Takeuchi, Masafumi Kawanishi, Megumi Nakanishi et al. · Arthritis & Rheumatology · 2022 · 65 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and safety of anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)

Yoshiya Tanaka, Masafumi Kawanishi, Megumi Nakanishi et al. · Modern Rheumatology · 2022 · 43 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial)

Yoshiya Tanaka, Masafumi Kawanishi, Megumi Nakanishi et al. · Modern Rheumatology · 2022 · 41 citations · Full text

Medicine, Immunology, Pharmacology +10

Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials

Tsutomu Takeuchi, Yukihiro Chino, Masafumi Kawanishi et al. · Arthritis Research & Therapy · 2023 · 34 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model

Norihisa Ishiwata, Kazuo Noguchi, Masafumi Kawanishi et al. · Life Sciences · 2007 · 16 citations

Medicine, Pharmacology, Pharmacotherapy +9